Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Selects 3rd Target in Immunocore Oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

GSK Selects 3rd Target in Immunocore Oncology Alliance

Will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GlaxoSmithKline has selected a third target under its ongoing oncology discovery collaboration with Immunocore Ltd. for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC molecule against the selected target which is relevant in multiple cancers. 

This is the third program to be initiated as part of the discovery collaboration from 2013. Immunocore is currently working on two other ImmTAC programmes under the agreement. The lead program is on track for an Investigational New Drug (IND) this year with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synovial sarcoma, melanoma and ovarian cancer. 

Dr. Bent Jakobsen, chief scientific officer at Immunocore, said, “The initiation of this new programme adds to a growing body of evidence that our ImmTAC technology has real potential to generate novel, potent drug candidates against disease targets which are difficult to address with other biologic platforms. ImmTAC molecules are relevant across a wide range of cancer types and have the ability to tackle solid ‘cold’, low mutation rate tumours – the majority of tumours which are difficult for other immuno-oncology drugs to address. We look forward to beginning work on this additional programme with GSK in oncology.”

Dr. Axel Hoos, senior vice president Therapeutic Area Head Oncology R&D Head, Immuno-Oncology at GSK, added, “We are pleased with the progress made in our ongoing collaboration with Immunocore and are excited to add a yet another target to the programme.  ImmTAC molecules have great potential among the third generation of immuno-oncology agents and we look forward to seeing this promising program progress.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics